These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8742803)

  • 21. Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.
    Cao C; Barros-Álvarez X; Zhang S; Kim K; Dämgen MA; Panova O; Suomivuori CM; Fay JF; Zhong X; Krumm BE; Gumpper RH; Seven AB; Robertson MJ; Krogan NJ; Hüttenhain R; Nichols DE; Dror RO; Skiniotis G; Roth BL
    Neuron; 2022 Oct; 110(19):3154-3167.e7. PubMed ID: 36087581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
    Marona-Lewicka D; Nichols DE
    Pharmacol Biochem Behav; 2007 Oct; 87(4):453-61. PubMed ID: 17618679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of LSD 25 and JB 318 on tests of visual and perceptual functions in man.
    OSTFELD AM
    Fed Proc; 1961 Dec; 20():876-84. PubMed ID: 14482599
    [No Abstract]   [Full Text] [Related]  

  • 24. [LSD-25, tranylcypromine and the serotoninergic system of the rat brain].
    Torre M; Bogetto F; Torre E
    Boll Soc Ital Biol Sper; 1976 Nov; 52(21):1842-5. PubMed ID: 1026258
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of the reactions induced by psilocybin and LSD-25 in man.
    ISBELL H
    Psychopharmacologia; 1959; 1():29-38. PubMed ID: 14405870
    [No Abstract]   [Full Text] [Related]  

  • 26. An electrographic study of d-lysergic acid diethylamide and nine congeners.
    Schweigerdt AK; Stewart AH; Himwich HE
    J Pharmacol Exp Ther; 1966 Mar; 151(3):353-9. PubMed ID: 5938474
    [No Abstract]   [Full Text] [Related]  

  • 27. Hallucinogens and Drosophila: linking serotonin receptor activation to behavior.
    Nichols CD; Ronesi J; Pratt W; Sanders-Bush E
    Neuroscience; 2002; 115(3):979-84. PubMed ID: 12435434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
    Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse consequences of lysergic acid diethylamide.
    Abraham HD; Aldridge AM
    Addiction; 1993 Oct; 88(10):1327-34. PubMed ID: 8251869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Psychopsychic correlations under the effect of psycholytics (LSD, psilocybin and similar drugs)].
    HOLFELD H
    Med Exp Int J Exp Med; 1961; 5():209-14. PubMed ID: 13908338
    [No Abstract]   [Full Text] [Related]  

  • 31. Cross tolerance between LSD and psilocybin.
    ISBELL H; WOLBACH AB; WIKLER A; MINER EJ
    Psychopharmacologia; 1961; 2():147-59. PubMed ID: 13717955
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
    Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
    J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indolealkylamine and phenalkylamine hallucinogens: a brief overview.
    Glennon RA; Rosecrans JA
    Neurosci Biobehav Rev; 1982; 6(4):489-97. PubMed ID: 6757811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain.
    Nichols CD; Sanders-Bush E
    Neuropsychopharmacology; 2002 May; 26(5):634-42. PubMed ID: 11927188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
    Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
    J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indolamine hallucinogens as MAO inhibitor agents--theoretical approach.
    Brandys Y; Yehuda S
    Int J Neurosci; 1983 Nov; 21(3-4):251-5. PubMed ID: 6671882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disrupted integration of sensory stimuli with information about the movement of the body as a mechanism explaining LSD-induced experience.
    Juszczak GR
    Med Hypotheses; 2017 Mar; 100():94-97. PubMed ID: 28236857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
    Liester MB
    Curr Drug Abuse Rev; 2014; 7(3):146-56. PubMed ID: 25563445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25.
    Gorodetzky CW; Isbell H
    Psychopharmacologia; 1964 Sep; 6(3):229-33. PubMed ID: 5319153
    [No Abstract]   [Full Text] [Related]  

  • 40. Is 2-bromo-D-lysergic acid diethylamide (BOL) an allosteric antagonist of serotonergic receptors in rabbit atria?
    Xu Z; Purdy RE
    Proc West Pharmacol Soc; 1988; 31():181-3. PubMed ID: 2905465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.